SEHK:8049Pharmaceuticals
Jilin Changlong Bio Pharmacy SEHK 8049 Margin Strength Reinforces Bullish Valuation Narratives
Jilin Province Huinan Changlong Bio-pharmacy (SEHK:8049) has posted its FY 2025 first half results with revenue of C¥438.9 million and basic EPS of C¥0.184, set against trailing 12 month revenue of C¥901.9 million and EPS of C¥0.355 that came alongside a 7.9% earnings uplift and net profit margins of 22.1%. Over the past year, the company has seen revenue move between C¥881.2 million and C¥926.9 million on a trailing 12 month basis, with basic EPS ranging from C¥0.327 to C¥0.355. This gives a...